{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:42:54Z","timestamp":1792640574698,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007185","name":"UC | University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable clinical efficacy against B-cell malignancies, yet marked vulnerability to antigen escape and tumor relapse exists. Here we report the rational design and optimization of bispecific CAR-T cells with robust activity against heterogeneous multiple myeloma (MM) that is resistant to conventional CAR-T cell therapy targeting B-cell maturation antigen (BCMA). We demonstrate that BCMA\/CS1 bispecific CAR-T cells exhibit superior CAR expression and function compared to T cells that co-express individual BCMA and CS1 CARs. Combination therapy with anti\u2013PD-1 antibody further accelerates the rate of initial tumor clearance in vivo, while CAR-T cell treatment alone achieves durable tumor-free survival even upon tumor re-challenge. Taken together, the BCMA\/CS1 bispecific CAR presents a promising treatment approach to prevent antigen escape in CAR-T cell therapy against MM, and the vertically integrated optimization process can be used to develop robust cell-based therapy against novel disease targets.<\/jats:p>","DOI":"10.1038\/s41467-020-16160-5","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:03:04Z","timestamp":1588917784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":199,"title":["Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma"],"prefix":"10.1038","volume":"11","author":[{"given":"Eugenia","family":"Zah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-1415","authenticated-orcid":false,"given":"Eunwoo","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinya","family":"Bhuvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uyen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda Y.","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley B.","family":"Gosliner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5583-119X","authenticated-orcid":false,"given":"Yvonne Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"16160_CR1","unstructured":"Cancer Facts and Figures 2019, American Cancer Society (2019).\u00a0https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2019\/cancer-facts-and-figures-2019.pdf."},{"key":"16160_CR2","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"98121","author":"AJ Cowan","year":"2018","unstructured":"Cowan, A. J. et al. Global burden of multiple myeloma. JAMA Oncol. 98121, 1221\u20131227 (2018).","journal-title":"JAMA Oncol."},{"key":"16160_CR3","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","volume":"125","author":"P Moreau","year":"2015","unstructured":"Moreau, P., Attal, M. & Facon, T. Frontline therapy of multiple myeloma. Blood 125, 3076\u20133085 (2015).","journal-title":"Blood"},{"key":"16160_CR4","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali, S. A. et al. T cells expressing an anti-B cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128, 1688\u20131701 (2016).","journal-title":"Blood"},{"key":"16160_CR5","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"J Brudno","year":"2018","unstructured":"Brudno, J. et al. T cells genetically modified to express an anti-B cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J. Clin. Oncol. 36, 2267\u20132280 (2018).","journal-title":"J. Clin. Oncol."},{"key":"16160_CR6","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.V130.Suppl_1.740.740","volume":"130","author":"JG Berdeja","year":"2017","unstructured":"Berdeja, J. G. et al. Durable clinical responses in heavily pretreated patients with relapsed\/refractory multiple myeloma: Updated results from a multicenter study of bb2121 anti-Bcma CAR T cell therapy. Blood 130, 740 (2017).","journal-title":"Blood"},{"key":"16160_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1182\/blood-2017-08-803551","volume":"130","author":"AD Cohen","year":"2017","unstructured":"Cohen, A. D. et al. Safety and efficacy of B cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM). Blood 130, 505 (2017).","journal-title":"Blood"},{"key":"16160_CR8","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1182\/blood-2017-02-769869","volume":"130","author":"EL Smith","year":"2017","unstructured":"Smith, E. L. et al. Development and evaluation of a human single chain variable fragment (scFv) derived Bcma rargeted CAR T cell vector leads to a high objective response rate in patients with advanced MM. Blood 130, 742 (2017).","journal-title":"Blood"},{"key":"16160_CR9","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1038\/mtna.2013.32","volume":"2","author":"Z Grada","year":"2013","unstructured":"Grada, Z. et al. TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol. Ther. Nucleic Acids 2, e105 (2013).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"16160_CR10","doi-asserted-by":"publisher","unstructured":"Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C. & Chen, Y. Y. T cells expressing CD19\/CD20 bi-specific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol. Res. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0231 (2016).","DOI":"10.1158\/2326-6066.CIR-15-0231"},{"key":"16160_CR11","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","volume":"126","author":"M Hegde","year":"2016","unstructured":"Hegde, M. et al. Tandem CAR T cells targeting HER2 and IL13R \u03b1 2 mitigate tumor antigen escape. J. Clin. Invest. 126, 3036\u20133052 (2016).","journal-title":"J. Clin. Invest."},{"key":"16160_CR12","first-page":"810","volume":"130","author":"H Qin","year":"2017","unstructured":"Qin, H. et al. Novel CD19\/CD22 Bicistronic chimeric antigen receptors outperform single or bivalent CARs in eradicating CD19+CD22+, CD19\u2212, and CD22\u2212 Pre-B Leukemia. Am. Soc. Hematol. 130, 810 (2017).","journal-title":"Am. Soc. Hematol."},{"key":"16160_CR13","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","volume":"131","author":"L Lee","year":"2018","unstructured":"Lee, L. et al. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. Blood 131, 746\u2013758 (2018).","journal-title":"Blood"},{"key":"16160_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"AJ Novak","year":"2004","unstructured":"Novak, A. J. et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103, 689\u2013694 (2004).","journal-title":"Blood"},{"key":"16160_CR15","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","volume":"106","author":"J Moreaux","year":"2005","unstructured":"Moreaux, J. et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106, 1021\u20131030 (2005).","journal-title":"Blood"},{"key":"16160_CR16","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/bjh.14145","volume":"174","author":"L Lee","year":"2016","unstructured":"Lee, L. et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br. J. Haematol. 174, 911\u2013922 (2016).","journal-title":"Br. J. Haematol."},{"key":"16160_CR17","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","volume":"14","author":"ED Hsi","year":"2008","unstructured":"Hsi, E. D. et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin. Cancer Res. 14, 2775\u20132784 (2008).","journal-title":"Clin. Cancer Res."},{"key":"16160_CR18","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","volume":"112","author":"Y-T Tai","year":"2008","unstructured":"Tai, Y.-T. et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu. Blood 112, 1329\u20131337 (2008).","journal-title":"Blood"},{"key":"16160_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","volume":"24","author":"X Wang","year":"2018","unstructured":"Wang, X. et al. Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma. Clin. Cancer Res. 24, 106\u2013119 (2018).","journal-title":"Clin. Cancer Res."},{"key":"16160_CR20","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","volume":"19","author":"M Hudecek","year":"2013","unstructured":"Hudecek, M. et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19, 3153\u20133164 (2013).","journal-title":"Clin. Cancer Res."},{"key":"16160_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","volume":"3","author":"M Hudecek","year":"2015","unstructured":"Hudecek, M. et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 3, 125\u2013135 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"16160_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature11220","volume":"487","author":"JR James","year":"2012","unstructured":"James, J. R. & Vale, R. D. Biophysical mechanism of T-cell receptor triggering in a reconstituted system. Nature 487, 64\u201369 (2012).","journal-title":"Nature"},{"key":"16160_CR23","unstructured":"Williams, M., Tso, Y., Landolfi, N. F., Powers, D. B. & Liu, G. Therapeutic use of anti-CS1 antibodies US (US Patents, 2010). https:\/\/patents.google.com\/patent\/US7709610B2\/en."},{"key":"16160_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/leu.2017.302","volume":"32","author":"KH Chen","year":"2018","unstructured":"Chen, K. H. et al. A compound chimeric antigen receptor strategy for targeting multiple myeloma. Leukemia 32, 402\u2013412 (2018).","journal-title":"Leukemia"},{"key":"16160_CR25","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.4049\/jimmunol.167.10.5517","volume":"167","author":"A Bouchon","year":"2001","unstructured":"Bouchon, A., Cella, M., Grierson, H. L., Cohen, J. I. & Colonna, M. Cutting edge: activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J. Immunol. 167, 5517\u20135521 (2001).","journal-title":"J. Immunol."},{"key":"16160_CR26","first-page":"1","volume":"1","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 1, 1\u201316 (2016).","journal-title":"J. Clin. Invest."},{"key":"16160_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1172\/JCI32103","volume":"118","author":"C Berger","year":"2008","unstructured":"Berger, C. et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118, 294\u2013305 (2008).","journal-title":"J. Clin. Invest."},{"key":"16160_CR28","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer, D. et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30, 492\u2013500 (2016).","journal-title":"Leukemia"},{"key":"16160_CR29","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu, Y. et al. Closely-related T-memory stem cells correlate with in-vivo expansion of CAR.CD19-T cells in patients and are preserved by IL-7 and IL-15. Blood 123, 3750\u20133759 (2014).","journal-title":"Blood"},{"key":"16160_CR30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","volume":"3","author":"MJ Frigault","year":"2015","unstructured":"Frigault, M. J. et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol. Res. 3, 356\u2013367 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"16160_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543, 113\u2013117 (2017).","journal-title":"Nature"},{"key":"16160_CR32","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","volume":"20","author":"V Verma","year":"2019","unstructured":"Verma, V. et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat. Immunol. 20, 1231\u20131243 (2019).","journal-title":"Nat. Immunol."},{"key":"16160_CR33","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00262-018-2244-7","volume":"67","author":"H Zelba","year":"2018","unstructured":"Zelba, H. et al. Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy. Cancer Immunol. Immunother. 67, 1845\u20131851 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"16160_CR34","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jcyt.2017.03.077","volume":"19","author":"M Rosenzweig","year":"2017","unstructured":"Rosenzweig, M. et al. Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis. Cytotherapy 19, 861\u2013866 (2017).","journal-title":"Cytotherapy"},{"key":"16160_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial, S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373, 621\u2013631 (2015).","journal-title":"N. Engl. J. Med."},{"key":"16160_CR36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/2040620716652862","volume":"7","author":"H Magen","year":"2016","unstructured":"Magen, H. & Muchtar, E. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther. Adv. Hematol. 7, 187\u2013195 (2016).","journal-title":"Ther. Adv. Hematol."},{"key":"16160_CR37","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","volume":"120","author":"JA Zonder","year":"2013","unstructured":"Zonder, J. A. et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120, 552\u2013559 (2013).","journal-title":"Blood"},{"key":"16160_CR38","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1089\/104303401753153947","volume":"12","author":"M Kumar","year":"2001","unstructured":"Kumar, M., Keller, B., Makalou, N. & Sutton, R. E. Systematic determination of the packaging limit of lentiviral vectors. Hum. Gene Ther. 12, 1893\u20131905 (2001).","journal-title":"Hum. Gene Ther."},{"key":"16160_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jbiotec.2010.07.010","volume":"150","author":"TJ Bos","year":"2010","unstructured":"Bos, T. J., De Bruyne, E., Van Lint, S., Heirman, C. & Vanderkerken, K. Large double copy vectors are functional but show a size-dependent decline in transduction efficiency. J. Biotechnol. 150, 37\u201340 (2010).","journal-title":"J. Biotechnol."},{"key":"16160_CR40","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1182\/blood.V126.23.4427.4427","volume":"126","author":"H Qin","year":"2015","unstructured":"Qin, H., Haso, W., Nguyen, S. M. & Fry, T. J. Preclinical development of bispecific chimeric antigen receptor targeting both CD19 and CD22. Blood 126, 4427 (2015).","journal-title":"Blood"},{"key":"16160_CR41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nmeth.1318","volume":"6","author":"DG Gibson","year":"2009","unstructured":"Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343\u2013345 (2009).","journal-title":"Nat. Methods"},{"key":"16160_CR42","unstructured":"Brogdon, J. et al. WO2016014565_Treatment of cancer using humanized anti-BCMA CAR.pdf. (US Patents, 2016). https:\/\/patents.google.com\/patent\/WO2016014565A2\/en."},{"key":"16160_CR43","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter, R. O. et al. B cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048\u20132060 (2013).","journal-title":"Clin. Cancer Res."},{"key":"16160_CR44","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.molonc.2015.03.010","volume":"9","author":"F Oden","year":"2015","unstructured":"Oden, F. et al. Potent anti-tumor response by targeting. Mol. Oncol. 9, 1348\u20131358 (2015).","journal-title":"Mol. Oncol."},{"key":"16160_CR45","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood.V128.22.379.379","volume":"128","author":"LSH Lee","year":"2016","unstructured":"Lee, L. S. H. et al. An APRIL based chimeric antigen receptor to simultaneously target BCMA and TACI in multiple myeloma (MM) has potent activity in vitro and in vivo. Blood 128, 379 (2016).","journal-title":"Blood"},{"key":"16160_CR46","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-13-2510","volume":"20","author":"J Chu","year":"2014","unstructured":"Chu, J. et al. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin. Cancer Res. 20, 3989\u20134000 (2014).","journal-title":"Clin. Cancer Res."},{"key":"16160_CR47","unstructured":"Yu, J., Hofmeister, C. & Chu, J. WO2014179759_CS1 CAR.pdf. (US Patents, 2014). https:\/\/patents.google.com\/patent\/US20160075784A1\/en."},{"key":"16160_CR48","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang, X. et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255\u20131263 (2011).","journal-title":"Blood"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16160-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16160-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16160-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T16:43:51Z","timestamp":1670258631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16160-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["16160"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-16160-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.03.12.989491","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,8]]},"assertion":[{"value":"5 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.Y.C. and E.Z. declare competing financial interest in the form of a patent application whose value may be affected by the publication of this work. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2283"}}